Clinical Trials Directory

Trials / Unknown

UnknownNCT01391052

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Scott and White Hospital & Clinic · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

Problematic uterine bleeding after the insertion of the LNG IUS is a well documented side effect. The levonorgestrel intrauterine system (LNG IUS) was approved for treatment of heavy menstrual bleeding (HMB) by the FDA in October 2009. To reduce the incidence and severity of post-insertional uterine bleeding, pretreatment with norethindrone acetate may effectively slough the endometrium prior to insertion of the LNG IUS.

Detailed description

This study will examine whether or not pretreatment with oral norethindrone acetate prior to the insertion of a hormonal intrauterine device will affect post-insertional uterine bleeding. The subjects enrolling in the study will have documented heavy menstrual bleeding (HMB) and desire the levonorgestrel intrauterine system (LNG IUS) (Mirena®, Bayer, Inc. Pittsburgh, PA) for symptomatic relief. HMB for this study is defined as heavy bleeding at regular intervals at least 20-40 days apart. Subjects will be randomized to one of two groups. One group will receive norethindrone acetate for two consecutive months prior to LNG IUS insertion while the other group will proceed with direct insertion of the LNG IUS with no hormonal pre-treatment. Subjects will be followed for a period of 180 days post LNG IUS insertion. Bleeding patterns will be recorded daily.

Conditions

Interventions

TypeNameDescription
DRUGNorethindrone acetate pretreatment5 mg tablets, three times a day for 21 days for 2 menstrual cycles.
OTHERNo pretreatmentLVN IUS is placed withour Norethindrone acetate pretreatment.

Timeline

Start date
2011-01-01
Primary completion
2013-01-01
Completion
2013-01-01
First posted
2011-07-11
Last updated
2011-07-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01391052. Inclusion in this directory is not an endorsement.